Virbac Reports Strong H1 Performance With Adjusted EBIT Margin of 18.8%
In the first half of 2026, Virbac reported revenue growth of +7.4% and an adjusted EBIT margin of 18.8%. The company attributed this performance to strong organic volume/mix effects (+5.4%) and price increases (~+2%). Both business segments—companion animals (+10.0%) and farm animals (+6.7%)—contributed significantly, with the Supercharge platforms (excluding Thyronorm) growing around 12% in CERS. The operating margin increased by 0.5 percentage points compared to H1 of 2025 due to a favorable product mix effect on gross margins, although partially offset by higher operational expenses from seasonal distribution effects between the first and second semesters. Consolidated net profit rose 5.9% year-over-year to €87.1 million. Net debt reached €196 million as of June 2026 compared to €173 million at December 2025, primarily due to seasonal working capital needs.
Topics: animal_health ebit_margin financial_performance revenue_growth